Bharvin Kumar Patel

This inventor holds 8 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 6 EPO patents. Top assignees: Eli Lilly and Company, Audion Therapeutics, Isis Pharmaceuticals, Inc.. Active years: 2009-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bharvin Kumar Patel. Retrieved from https://idiyas.com/inventor/bharvin-kumar-patel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 1)

% Patents Active = 87.5

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 138(Granted Patents)

Location History:

Westfield, IN (US) (2009 - 2015)
Carmel, IN (US) (2019)
Indianapolis, IN (US) (2020 - 2023)

Company Filing History:

8 out of 4,509

Eli Lilly and Company

Isis Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2023

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11826317 - Combination therapy with notch and PD-1 or PD-L1 inhibitors (2023-11-28),

2. 11564929 - Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer (2023-01-31),

3. 11298362 - Combination therapy with Notch and CDK4/6 inhibitors for the treatment of cancer (2022-04-12),

4. 10688104 - Combination therapy with Notch and PD-1 or PD-L1 inhibitors (2020-06-23),

5. 10450317 - Notch pathway signaling inhibitor compounds (2019-10-22),

6. 9000023 - Disubstituted phthalazine hedgehog pathway antagonists (2015-04-07),

7. 8273742 - Disubstituted phthalazine hedgehog pathway antagonists (2012-09-25),

8. 7541344 - Modulation of survivin expression (2009-06-02),

Title: Bharvin Kumar Patel: Innovator in Cancer Treatment

Introduction

Bharvin Kumar Patel is a notable inventor based in Westfield, IN (US). He has made significant contributions to the field of cancer treatment, holding a total of 8 patents. His work focuses on innovative combination therapies that target various types of cancer.

Latest Patents

Patel's latest patents include groundbreaking inventions such as "Combination therapy with Notch and PD-1 or PD-L1 inhibitors." This invention provides medicaments for treating a wide range of cancers, including T-cell acute lymphoblastic leukemia, breast cancer, and melanoma, among others. Another significant patent is "Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer," which also addresses multiple cancer types and offers new therapeutic options for patients.

Career Highlights

Throughout his career, Bharvin Kumar Patel has worked with prominent companies in the pharmaceutical industry, including Eli Lilly and Company and Isis Pharmaceuticals, Inc. His experience in these organizations has contributed to his expertise in developing innovative cancer treatments.

Collaborations

Patel has collaborated with notable professionals in his field, including Philip Arthur Hipskind and Mark Harrath Bender. These collaborations have further enhanced his research and development efforts in cancer therapies.

Conclusion

Bharvin Kumar Patel is a distinguished inventor whose work in cancer treatment has the potential to improve patient outcomes significantly. His innovative approaches and collaborations reflect his commitment to advancing medical science.

Profile summary based on public USPTO records.